Top

Published in:

Open Access 01-03-2025 | Metastasis | REVIEW

Neuropeptide Y in cancer—biological functions and potential clinical implications

Authors: Dawid Sigorski, Aleksandra Sejda, Nouran Abualsaud, Ewa Krawczyk, Ewa Izycka-Swieszewska, Joanna Kitlinska

Published in: Cancer and Metastasis Reviews | Issue 1/2025

Abstract

Neuropeptide Y (NPY) is a sympathetic neurotransmitter widely distributed in the peripheral and central nervous system, affecting many physiological functions. Consequently, dysregulation of the NPY system contributes to numerous pathological disorders, including stress, obesity, and cancer. The pleiotropic functions of NPY in humans are mediated by G protein-coupled receptors (Y1R, Y2R, Y5R), which activate several signaling pathways and thereby regulate cell growth, differentiation, apoptosis, proliferation, angiogenesis, and metabolism. These activities of NPY are highly relevant to tumor biology and known hallmarks of cancer, including sustained proliferative potential, resisting cell death, angiogenesis, invasion, and metastases. In this comprehensive review, we describe the cellular functions of NPY and discuss its role in cancer pathobiology, as well as provide the current state of knowledge pertaining to NPY and its receptors in various cancer types. Moreover, we focus on potential clinical applications targeting the NPY system, such as its role as a prognostic and predictive factor, as well as its utility in cancer diagnostics, imaging, and treatment. Altogether, growing evidence supports the significant role of the NPY system in tumor pathobiology and implicates its potential therapeutic and diagnostic value in modern oncology.

Anderson, N. M., & Simon, M. C. (2020). The tumor microenvironment. Current Biology, 30, R921–R925. https://doi.org/10.1016/J.CUB.2020.06.081CrossRefPubMed

Pedrazzini, T., Pralong, F., & Grouzmann, E. (2003). Neuropeptide Y: The universal soldier. Cellular and Molecular Life Sciences, 60, 350–377. https://doi.org/10.1007/S000180300029CrossRefPubMedPubMedCentral

Tatemoto, K., Carlquist, M., & Mutt, V. (1982). Neuropeptide Y-A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature, 296, 659–660. https://doi.org/10.1038/296659a0CrossRefPubMed

Hirsch, D., & Zukowska, Z. (2012). NPY and stress 30 years later: The peripheral view. Cellular and Molecular Neurobiology, 32, 645. https://doi.org/10.1007/S10571-011-9793-ZCrossRefPubMedPubMedCentral

Heilig, M. (2004). The NPY system in stress, anxiety and depression. Neuropeptides, 38, 213–224. https://doi.org/10.1016/j.npep.2004.05.002CrossRefPubMed

Shende, P., & Desai, D. (2020). Physiological and therapeutic roles of neuropeptide Y on biological functions. Advances in Experimental Medicine and Biology, 1237, 37–47. https://doi.org/10.1007/5584_2019_427/COVERCrossRefPubMed

Chen, W. C., Liu, Y. B., Liu, W. F., Zhou, Y. Y., He, H. F., & Lin, S. (2020). Neuropeptide Y is an immunomodulatory factor: Direct and indirect. Frontiers in immunology, 11, 580378. https://doi.org/10.3389/fimmu.2020.580378CrossRefPubMedPubMedCentral

Tan, C. M. J., Green, P., Tapoulal, N., Lewandowski, A. J., Leeson, P., & Herring, N. (2018). The role of neuropeptide Y in cardiovascular health and disease. Frontiers in Physiology, 9, 1281. https://doi.org/10.3389/FPHYS.2018.01281CrossRefPubMedPubMedCentral

Zhang, L., Bijker, M. S., & Herzog, H. (2011). The neuropeptide Y system: Pathophysiological and therapeutic implications in obesity and cancer. Pharmacology and Therapeutics, 131, 91–113. https://doi.org/10.1016/j.pharmthera.2011.03.011CrossRefPubMed

10.

Kitlinska, K., Kuo, L. E., Pons, J., Zukowska, Z., & Feuerstein, G. Z. (2005). NPY as a pleiotropic growth factor. The NPY family of peptides in immune disorders, inflammation, angiogenesis and cáncer, pp. 189–200. https://doi.org/10.1007/3-7643-7427-6_12.

11.

Liu, L., Xu, Q., Cheng, L., Ma, C., Xiao, L., Xu, D., Gao, Y., Wang, J., & Song, H. (2015). NPY1R is a novel peripheral blood marker predictive of metastasis and prognosis in breast cancer patients. Oncology Letters, 9, 891. https://doi.org/10.3892/OL.2014.2721CrossRefPubMed

12.

Ruscica, M., Dozio, E., Motta, M., & Magni, P. (2005). NPY family of peptides in endocrine, breast and prostate tumors. In: The NPY family of peptides in immune disorders, inflammation, angiogenesis and cancer, Birkhäuser-Verlag, Basel, pp. 237–248. https://doi.org/10.1007/3-7643-7427-6_15.

13.

Körner, M., & Reubi, J. C. (2007). NPY receptors in human cancer: A review of current knowledge. Peptides (N.Y.), 28, 419–425. https://doi.org/10.1016/j.peptides.2006.08.037CrossRef

14.

Sánchez, M. L., Rodríguez, F. D., & Coveñas, R. (2023). Neuropeptide Y peptide family and cancer: Antitumor therapeutic strategies. International Journal of Molecular Sciences, 24(12), 9962. https://doi.org/10.3390/IJMS24129962CrossRefPubMedPubMedCentral

15.

Tatemoto, K. (2004). Neuropeptide Y: History and overview. pp. 1–21. https://doi.org/10.1007/978-3-642-18764-3_1.

16.

Larhammar, D., Blomqvist, A. G., & Söderberg, C. (1993). Evolution of neuropeptide Y and its related peptides. Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, 106(3), 743-752. http://www.ncbi.nlm.nih.gov/pubmed/7905810. Accessed 21 June 2017.

17.

Takeuchi, T., Gumucio, D. L., Yamada, T., Meisler, M. H., Minth, C. D., Dixon, J. E., Eddy, R. E., & Shows, T. B. (1986). Genes encoding pancreatic polypeptide and neuropeptide Y are on human chromosomes 17 and 7. The Journal of Clinical Investigation, 77, 1038–1041. https://doi.org/10.1172/JCI112357CrossRefPubMedPubMedCentral

18.

Chronwall, B. M., DiMaggio, D. A., Massari, V. J., Pickel, V. M., Ruggiero, D. A., & O'donohue, T. L. (1985). The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience, 15(4), 1159-1181. http://www.ncbi.nlm.nih.gov/pubmed/3900805. Accessed 21 June 2017.

19.

Morris, J. L. (1999). Cotransmission from sympathetic vasoconstrictor neurons to small cutaneous arteries in vivo. American Journal of Physiology-Heart and Circulatory Physiology, 277(1), H58-H64. http://www.ncbi.nlm.nih.gov/pubmed/10409182. Accessed 22 June 2017.

20.

Lundberg, J. M., Franco‐Cereceda, A., Hemsen, A., Lacroix, J. S., & Pernow, J. (1990). Pharmacology of noradrenaline and neuropeptide tyrosine (NPY)‐mediated sympathetic cotransmission. Fundamental and Clinical Pharmacology, 4(4), 373-391. http://www.ncbi.nlm.nih.gov/pubmed/2170253. Accessed 22 June 2017.

21.

Magnussen, C., Hung, S. P., & Ribeiro-da-Silva, A. (2015). Novel expression pattern of neuropeptide Y immunoreactivity in the peripheral nervous system in a rat model of neuropathic pain. Molecular Pain, 11, s12990-015. https://doi.org/10.1186/S12990-015-0029-YCrossRef

22.

Leblanc, G. G., Trimmer, B. A., & Landis, S. (1987). Neuropeptide Y-like immunoreactivity in rat cranial parasympathetic neurons: Coexistence with vasoactive intestinal peptide and choline acetyltransferase. Proceedings of the National Academy of Sciences, 84(10), 3511–3515. https://doi.org/10.1073/PNAS.84.10.3511CrossRef

23.

Kuo, L. E., Kitlinska, J. B., Tilan, J. U., Li, L., Baker, S. B., Johnson, M. D., Lee, E. W., Burnett, M. S., Fricke, S. T., Kvetnansky, R., Herzog, H., & Zukowska, Z. (2007). Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nature Medicine, 13, 803–811. https://doi.org/10.1038/NM1611CrossRefPubMed

24.

Lee, E. W., Michalkiewicz, M., Kitlinska, J., Kalezic, I., Switalska, H., Yoo, P., Sangkharat, A., Ji, H., Li, L., Michalkiewicz, T., Ljubisavljevic, M., Johansson, H., Grant, D. S., & Zukowska, Z. (2003). Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. Journal of Clinical Investigation, 111, 1853. https://doi.org/10.1172/JCI16929CrossRefPubMedPubMedCentral

25.

Cheng, Y., Tang, X. Y., Li, Y. X., Zhao, D. D., Cao, Q. H., Wu, H. X., Yang, H. B., Hao, K., & Yang, Y. (2019). Depression-induced neuropeptide y secretion promotes prostate cancer growth by recruiting myeloid cells. Clinical Cancer Research, 25, 2621–2632. https://doi.org/10.1158/1078-0432.CCR-18-2912/74313/AM/DEPRESSION-INDUCED-NEUROPEPTIDE-Y-SECRETIONCrossRefPubMed

26.

Kuo, L. E., & Zukowska, Z. (2007). Stress, NPY and vascular remodeling: Implications for stress-related diseases. Peptides, 28(2), 435–440. https://doi.org/10.1016/J.PEPTIDES.2006.08.035CrossRefPubMedPubMedCentral

27.

Tjon-Kon-Fat, L. A., Lundholm, M., Schröder, M., Wurdinger, T., Thellenberg-Karlsson, C., Widmark, A., Wikström, P., & Nilsson, R. J. A. (2018). Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients. Prostate, 78, 48–53. https://doi.org/10.1002/PROS.23443CrossRefPubMed

28.

Paiva, S. P. C., Veloso, C. A., Campos, F. F. C., Carneiro, M. M., Tilan, J. U., Wang, H., Umans, J. G., Zukowska, Z., & Kitlinska, J. (2016). Elevated levels of neuropeptide Y in preeclampsia: A pilot study implicating a role for stress in pathogenesis of the disease. Neuropeptides, 55, 127–135. https://doi.org/10.1016/J.NPEP.2015.09.006CrossRefPubMed

29.

Tilan, J. U., Everhart, L. M., Abe, K., Kuo-Bonde, L., Chalothorn, D., Kitlinska, J., Burnett, M. S., Epstein, S. E., Faber, J. E., & Zukowska, Z. (2013). Platelet neuropeptide Y is critical for ischemic revascularization in mice. The FASEB Journal, 27, 2244–2255. https://doi.org/10.1096/FJ.12-213546CrossRefPubMedPubMedCentral

30.

Li, L., Lee, E. W., Ji, H., & Zukowska, Z. (2003). Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 1204–1210. https://doi.org/10.1161/01.ATV.0000071349.30914.25CrossRefPubMed

31.

Tatemoto, K. (1982). Neuropeptide Y: Complete amino acid sequence of the brain peptide. Proc Natl Acad Sci U S A, 79, 5485–5489. https://doi.org/10.1073/PNAS.79.18.5485CrossRefPubMedPubMedCentral

32.

Minth, C. D., Andrews, P. C., & Dixon, J. E. (1986). Characterization, sequence, and expression of the cloned human neuropeptide Y gene*, of biological chemistry chemists. Inc, 261, 11974–11979. https://doi.org/10.1016/S0021-9258(18)67189-3CrossRef

33.

Grouzmann, E., & Brakch, N. (2005). NPY processing in neuronal and non-neuronal tissues by proconvertases. The NPY family of peptides in immune disorders, inflammation, angiogenesis and cáncer. 63–74. https://doi.org/10.1007/3-7643-7427-6_3.

34.

von Hörsten, S., Hoffmann, T., Alfalah, M., Wrann, C. D., Karl, T., Pabst, R., & Bedoui, S. (2004). PP, PYY and NPY: Synthesis, storage, release and degradation. 23–44. https://doi.org/10.1007/978-3-642-18764-3_2.

35.

Mentlein, R. (n.d.) Dipeptidyl-peptidase IV and aminopeptidase P: Molecular switches of NPY/PYY receptor affinities. In: The NPY family of peptides in immune disorders, inflammation, angiogenesis and cancer, Birkhauser-Verlag. Basel, pp. 75–84. https://doi.org/10.1007/3-7643-7427-6_4.

36.

Lu, C., Tilan, J. U., Everhart, L., Czarnecka, M., Soldin, S. J., Mendu, D. R., Jeha, D., Hanafy, J., Lee, C. K., Sun, J., Izycka-Swieszewska, E., Toretsky, J. A., & Kitlinska, J. (2011). Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: Implications for tumor biology and therapy*. Journal of Biological Chemistry, 286, 27494. https://doi.org/10.1074/JBC.M111.224089CrossRefPubMedPubMedCentral

37.

Bjelke, J. R., Christensen, J., Nielsen, P. F., Branner, S., Kanstrup, A. B., Wagtmann, N., & Rasmussen, H. B. (2006). Dipeptidyl peptidases 8 and 9: Specificity and molecular characterization compared with dipeptidyl peptidase IV. The Biochemical Journal, 396, 391–399. https://doi.org/10.1042/BJ20060079CrossRefPubMedPubMedCentral

38.

Pedragosa-Badia, X., Stichel, J., & Beck-Sickinger, A. G. (2013). Neuropeptide y receptors: How to get subtype selectivity. Front Endocrinol (Lausanne), 4, 35266. https://doi.org/10.3389/FENDO.2013.00005/BIBTEXCrossRef

39.

Bard, J. A., Walker, M. W., Branchek, T. A., & Weinshank, R. L. (1995). Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. Journal of Biological Chemistry, 270, 26762–26765. https://doi.org/10.1074/JBC.270.45.26762CrossRefPubMed

40.

Ringvall, M., Berglund, M. M., & Larhammar, D. (1997). Multiplicity of neuropeptide Y receptors: Cloning of a third distinct subtype in the zebrafish. Biochemical and Biophysical Research Communications, 241, 749–755. https://doi.org/10.1006/BBRC.1997.7886CrossRefPubMed

41.

Park, C., Kim, J., Ko, S. B., Choi, Y. K., Jeong, H., Woo, H., Kang, H., Bang, I., Kim, S. A., Yoon, T. Y., & Seok, C. (2022). Structural basis of neuropeptide Y signaling through Y1 receptor. Nature Communications., 13(1), 853. https://doi.org/10.1038/S41467-022-28510-6CrossRefPubMedPubMedCentral

42.

Tilan, J. U., Lu, C., Galli, S., Izycka-Swieszewska, E., Earnest, J. P., Shabbir, A., Everhart, L. M., Wang, S., Martin, S., Horton, M., & Mahajan, A. (2013). Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects. Oncotarget., 4(12), 2487. https://doi.org/10.18632/ONCOTARGET.1604CrossRefPubMedPubMedCentral

43.

Kilpatrick, L. E., Humphrys, L. J., & Holliday, N. D. (2015). A G protein-coupled receptor dimer imaging assay reveals selectively modified pharmacology of neuropeptide Y Y1/Y5 receptor heterodimers. Molecular Pharmacology, 87, 718–732. https://doi.org/10.1124/MOL.114.095356CrossRefPubMed

44.

Czarnecka, M., Lu, C., Pons, J., Maheswaran, I., Ciborowski, P., Zhang, L., Cheema, A., & Kitlinska, J. (2019). Neuropeptide Y receptor interactions regulate its mitogenic activity. Neuropeptides, 73, 11–24. https://doi.org/10.1016/J.NPEP.2018.11.008CrossRefPubMed

45.

Gehlert, D. R., Schober, D. A., Morin, M., & Berglund, M. M. (2007). Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties. Biochemical Pharmacology, 74, 1652–1664. https://doi.org/10.1016/J.BCP.2007.08.017CrossRefPubMed

46.

Pons, J., Kitlinska, J., Ji, H., Lee, E. W., & Zukowska, Z. (2003). Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: Synergetic interactions with the beta-adrenergic system. Canadian Journal of Physiology and Pharmacology, 81, 177–185. https://doi.org/10.1139/Y02-166CrossRefPubMed

47.

Movafagh, S., Hobson, J. P., Spiegel, S., Kleinman, H. K., Zukowska, Z., Movafagh, S., Hobson, J. P., Spiegel, S., Kleinman, H. K., & Zukowska, Z. (2006). Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. The FASEB Journal, 20, 1924–1926. https://doi.org/10.1096/FJ.05-4770FJECrossRefPubMed

48.

Czarnecka, M., Trinh, E., Lu, C., Kuan-Celarier, A., Galli, S., Hong, S.-H., Tilan, J. U., Talisman, N., Izycka-Swieszewska, E., Tsuei, J., Yang, C., Martin, S., Horton, M., Christian, D., Everhart, L., Maheswaran, I., & Kitlinska, J. (2015). Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: Implications for tumor chemoresistance. Oncogene, 34, 3131–3143. https://doi.org/10.1038/onc.2014.253CrossRefPubMed

49.

Du, P., Salon, J. A., Tamm, J. A., Hou, C., Cui, W., Walker, M. W., Adham, N., Dhanoa, D. S., Islam, I., Vaysse, P. J. J., Dowling, B., Shifman, Y., Boyle, N., Rueger, H., Schmidlin, T., Yamaguchi, Y., Branchek, T. A., Weinshank, R. L., & Gluchowski, C. (1997). Modeling the G-protein-coupled neuropeptide Y Y1 receptor agonist and antagonist binding sites. Protein Engineering, 10, 109–117. https://doi.org/10.1093/PROTEIN/10.2.109CrossRefPubMed

50.

Aakerlund, L., Gether, U., Fuhlendorff, J., Schwartz, T. W., & Thastrup, O. (1990). Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Letters, 260, 73–78. https://doi.org/10.1016/0014-5793(90)80069-UCrossRefPubMed

51.

Sheriff, S., Ali, M., Yahya, A., Haider, K. H., Balasubramaniam, A., & Amlal, H. (2010). Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line. Molecular Cancer Research, 8, 604–614. https://doi.org/10.1158/1541-7786.MCR-09-0301CrossRefPubMed

52.

Pons, J., Kitlinska, J., Jacques, D., Perreault, C., Nader, M., Everhart, L., Zhang, Y., & Zukowska, Z. (2008). Interactions of multiple signaling pathways in neuropeptide Y-mediated bimodal vascular smooth muscle cell growth. Canadian Journal of Physiology and Pharmacology, 86, 438–448. https://doi.org/10.1139/Y08-054CrossRefPubMedPubMedCentral

53.

Bischoff, A., Püttmann, K., Kötting, A., Moser, C., Buschauer, A., & Michel, M. C. (2001). Limited signal transduction repertoire of human Y5 neuropeptide Y receptors expressed in HEC-1B cells. Peptides, 22(3), 387–394. https://doi.org/10.1016/S0196-9781(01)00346-1CrossRefPubMed

54.

Pellieux, C., Sauthier, T., Domenighetti, A., Marsh, D. J., Palmiter, R. D., Brunner, H. R., & Pedrazzini, T. (2000). Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proc Natl Acad Sci U S A, 97, 1595–1600.CrossRefPubMedPubMedCentral

55.

Sheriff, S., Dayal, R., Kasckow, J., Regmi, A., Chance, W., Fischer, J., & Balasubramaniam, A. (1998). NPY upregulates genes containing cyclic AMP response element in human neuroblastoma cell lines bearing Y1 and Y2 receptors: Involvement of CREB. Regulatory Peptides, 75–76, 309–318. https://doi.org/10.1016/S0167-0115(98)00083-4CrossRefPubMed

56.

Lee, D. Y., Hong, S. H., Kim, B., Lee, D. S., Yu, K., & Lee, K. S. (2018). Neuropeptide Y mitigates ER stress-induced neuronal cell death by activating the PI3K-XBP1 pathway. European Journal of Cell Biology, 97, 339–348. https://doi.org/10.1016/J.EJCB.2018.04.003CrossRefPubMed

57.

Lu, C., Mahajan, A., Hong, S.-H., Galli, S., Zhu, S., Tilan, J. U., Abualsaud, N., Adnani, M., Chung, S., Elmansy, N., Rodgers, J., Rodriguez, O., Albanese, C., Wang, H., Regan, M., Zgonc, V., Blancato, J., Krawczyk, E., Gallicano, G. I., … Kitlinska, J. (2022). Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma. Nature Communications, 13, 2323. https://doi.org/10.1038/S41467-022-29898-XCrossRefPubMedPubMedCentral

58.

Abualsaud, N., Caprio, L., Galli, S., Krawczyk, E., Alamri, L., Zhu, S., Gallicano, G. I., & Kitlinska, J. (2021). Neuropeptide Y/Y5 receptor pathway stimulates neuroblastoma cell motility through RhoA activation. Frontiers in Cell and Developmental Biology., 8, 627090. https://doi.org/10.3389/FCELL.2020.627090CrossRefPubMedPubMedCentral

59.

Sun, Q. Q., Huguenard, J. R., & Prince, D. A. (2001). Neuropeptide Y receptors differentially modulate G-protein-activated inwardly rectifying K+ channels and high-voltage-activated Ca2+ channels in rat thalamic neurons. Journal of Physiology, 531, 67–79. https://doi.org/10.1111/J.1469-7793.2001.0067J.XCrossRefPubMedPubMedCentral

60.

Wanka, L., Babilon, S., Kaiser, A., Mörl, K., & Beck-Sickinger, A. G. (2018). Different mode of arrestin-3 binding at the human Y1 and Y2 receptor. Cellular Signalling, 50, 58–71. https://doi.org/10.1016/J.CELLSIG.2018.06.010CrossRefPubMed

61.

Gicquiaux, H., Lecat, S., Gaire, M., Dieterlen, A., Mély, Y., Takeda, K., Bucher, B., & Galzi, J. L. (2002). Rapid internalization and recycling of the human neuropeptide Y Y(1) receptor. Journal of Biological Chemistry, 277, 6645–6655. https://doi.org/10.1074/JBC.M107224200CrossRefPubMed

62.

Hofmann, S., Bellmann-Sickert, K., & Beck-Sickinger, A. G. (2020). Chemical modification of neuropeptide Y for human Y1 receptor targeting in health and disease. Biological Chemistry, 400, 299–311. https://doi.org/10.1515/HSZ-2018-0364/ASSET/GRAPHIC/J_HSZ-2018-0364_FIG_006.JPGCrossRef

63.

Brothers, S. P., & Wahlestedt, C. (2010). Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Molecular Medicine, 2, 429–439. https://doi.org/10.1002/EMMM.201000100CrossRefPubMedPubMedCentral

64.

Loh, K., Zhang, L., Brandon, A., Wang, Q., Begg, D., Qi, Y., Fu, M., Kulkarni, R., Teo, J., Baldock, P., Brüning, J. C., Cooney, G., Neely, G., & Herzog, H. (2017). Insulin controls food intake and energy balance via NPY neurons. Molecular Metabolism, 6, 574. https://doi.org/10.1016/J.MOLMET.2017.03.013CrossRefPubMedPubMedCentral

65.

Clark, J. T., Kalra, P. S., Crowley, W. R., & Kalra, S. P. (1984). Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology, 115, 427–429. https://doi.org/10.1210/ENDO-115-1-427CrossRefPubMed

66.

Huang, Y., Lin, X., & Lin, S. (2021). Neuropeptide Y and metabolism syndrome: An update on perspectives of clinical therapeutic intervention strategies. Frontiers in Cell and Developmental Biology, 9, 695623. https://doi.org/10.3389/FCELL.2021.695623/BIBTEXCrossRefPubMedPubMedCentral

67.

Ruohonen, S. T., Vähätalo, L. H., & Savontaus, E. (2012). Diet-induced obesity in mice overexpressing neuropeptide y in noradrenergic neurons. International journal of peptides, 2012(1), 452524. https://doi.org/10.1155/2012/452524CrossRefPubMedPubMedCentral

68.

Sun, W. W., Zhu, P., Shi, Y. C., Zhang, C. L., Huang, X. F., Liang, S. Y., Song, Z. Y., & Lin, S. (2017). Current views on neuropeptide y and diabetes-related atherosclerosis. Diabetes and Vascular Disease Research, 14, 277–284. https://doi.org/10.1177/1479164117704380/ASSET/IMAGES/LARGE/10.1177_1479164117704380-FIG1.JPEGCrossRefPubMed

69.

Heilig, M., Söderpalm, B., Engel, J. A., & Widerlöv, E. (1989). Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl), 98, 524–529. https://doi.org/10.1007/BF00441953CrossRefPubMed

70.

Li, C., Wu, X., Liu, S., Zhao, Y., Zhu, J., & Liu, K. (2019). Roles of neuropeptide Y in neurodegenerative and neuroimmune diseases. Frontiers in Neuroscience, 13, 869. https://doi.org/10.3389/FNINS.2019.00869CrossRefPubMedPubMedCentral

71.

Hansel, D. E., Eipper, B. A., & Ronnett, G. V. (2001). Neuropeptide Y functions as a neuroproliferative factor. Nature, 410, 940–944. https://doi.org/10.1038/35073601CrossRefPubMed

72.

Reichmann, F., & Holzer, P. (2016). Neuropeptide Y: A stressful review. Neuropeptides, 55, 99. https://doi.org/10.1016/J.NPEP.2015.09.008CrossRefPubMed

73.

Westfall, T. C., Carpentier, S., Chen, X., Beinfeld, M. C., Naes, L., & Meldrum, M. J. (1987). Prejunctional and postjunctional effects of neuropeptide Y at the noradrenergic neuroeffector junction of the perfused mesenteric arterial bed of the rat. Journal of Cardiovascular Pharmacology, 10, 716–722. https://doi.org/10.1097/00005344-198712000-00016CrossRefPubMed

74.

Han, S., Yang, C. L., Chen, X., Naes, L., Cox, B. F., & Westfall, T. (1998). Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction. American Journal of Physiology-Heart and Circulatory Physiology, 274(1), H290–H294. https://doi.org/10.1152/AJPHEART.1998.274.1.H290CrossRef

75.

Zhu, P., Sun, W., Zhang, C., Song, Z., & Lin, S. (2016). The role of neuropeptide Y in the pathophysiology of atherosclerotic cardiovascular disease. International Journal of Cardiology, 220, 235–241. https://doi.org/10.1016/J.IJCARD.2016.06.138CrossRefPubMed

76.

Li, L., Najafi, A. H., Kitlinska, J. B., Neville, R., Laredo, J., Epstein, S. E., Burnett, M. S., & Zukowska, Z. (2011). Of mice and men: Neuropeptide Y and its receptors are associated with atherosclerotic lesion burden and vulnerability. Journal of Cardiovascular Translational Research, 4, 351–362. https://doi.org/10.1007/S12265-011-9271-5CrossRefPubMed

77.

Wheway, J., Herzog, H., & Mackay, F. (2007). NPY and receptors in immune and inflammatory diseases. Current Topics in Medicinal Chemistry, 7, 1743–1752. https://doi.org/10.2174/156802607782341046CrossRefPubMed

78.

Bedoui, S., Pabst, R., & von Hörsten, S. (2004). NPY and immune functions: implications for health and disease. Neuropeptide Y and Related Peptides, 409-445. https://doi.org/10.1007/978-3-642-18764-3_14.

79.

Yu, J., Xiao, K., Chen, X., Deng, L., Zhang, L., Li, Y., Gao, A., Gao, J., Wu, C., Yang, X., Zhou, Q., Yang, J., Bao, C., Jiao, J., Cheng, S., Guo, Z., Xu, W., Cao, X., Guo, Z., … Cao, G. (2022). Neuron-derived neuropeptide Y fine-tunes the splenic immune responses. Neuron, 110, 1327-1339.e6. https://doi.org/10.1016/J.NEURON.2022.01.010CrossRefPubMed

80.

Wheway, J., Herzog, H., & Mackay, F. (2007). The Y1 receptor for NPY: A key modulator of the adaptive immune system. Peptides, 28(2), 453–458. https://doi.org/10.1016/J.PEPTIDES.2006.09.030CrossRefPubMed

81.

Farzi, A., Reichmann, F., & Holzer, P. (2015). The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour. Acta Psychologica, 213, 603–627. https://doi.org/10.1111/APHA.12445CrossRef

82.

Chen, Q. C., & Zhang, Y. (2022). The role of NPY in the regulation of bone metabolism. Frontiers in Endocrinology, 13, 833485. https://doi.org/10.3389/FENDO.2022.833485CrossRefPubMedPubMedCentral

83.

Pati, S., Irfan, W., Jameel, A., Ahmed, S., & Shahid, R. K. (2023). Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management. Cancers, 15(2), 485. https://doi.org/10.3390/CANCERS15020485CrossRefPubMedPubMedCentral

84.

Al-Mansoori, L., Al-Jaber, H., Prince, M. S., & Elrayess, M. A. (2022). Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance. Inflammation, 45, 31. https://doi.org/10.1007/S10753-021-01559-ZCrossRefPubMed

85.

Chen, W. C., Bin Liu, Y., Liu, W. F., Zhou, Y. Y., He, H. F., & Lin, S. (2020). Neuropeptide Y is an immunomodulatory factor: Direct and indirect. Frontiers of Immunology, 11, 2624. https://doi.org/10.3389/FIMMU.2020.580378/BIBTEXCrossRef

86.

Moreno-Smith, M., Lutgendorf, S. K., & Sood, A. K. (2010). Impact of stress on cancer metastasis. Future Oncology, 6, 1863. https://doi.org/10.2217/FON.10.142CrossRefPubMed

87.

Mohammadpour, H., Bucsek, M. J., Hylander, B. L., & Repasky, E. A. (2019). Depression stresses the immune response and promotes prostate cancer growth. Clinical Cancer Research, 25, 2363–2365. https://doi.org/10.1158/1078-0432.CCR-18-3980/74536/AM/DEPRESSION-STRESSES-THE-IMMUNE-RESPONSE-ANDCrossRefPubMedPubMedCentral

88.

Ekstrand, A. J., Cao, R., Björndahl, M., Nyström, S., Jönsson-Rylander, A. C., Hassani, H., Hallberg, B., Nordlander, M., & Cao, Y. (2003). Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A, 100, 6033–6038. https://doi.org/10.1073/PNAS.1135965100CrossRefPubMedPubMedCentral

89.

Saraf, R., Mahmood, F., Amir, R., & Matyal, R. (2016). Neuropeptide Y is an angiogenic factor in cardiovascular regeneration. European Journal of Pharmacology, 776, 64–70. https://doi.org/10.1016/J.EJPHAR.2016.02.033CrossRefPubMed

90.

Peng, S., Zhou, Y. L., Song, Z. Y., & Lin, S. (2017). Effects of neuropeptide Y on stem cells and their potential applications in disease therapy. Stem Cells Int, 2017, 6823917–6823917. https://doi.org/10.1155/2017/6823917CrossRefPubMedPubMedCentral

91.

Tilan, J., & Kitlinska, J. (2016). Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology. Neuropeptides, 55, 55. https://doi.org/10.1016/J.NPEP.2015.10.005CrossRefPubMed

92.

Pellieux, C., Sauthier, T., Domenighetti, A., Marsh, D. J., Palmiter, R. D., Brunner, H. R., & Pedrazzini, T. (2000). Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proceedings of the National Academy of Sciences, 97(4), 1595-1600. www.pnas.orgcgi10.1073pnas.030533197. Accessed 15 Nov 2022.

93.

Zhang, P., Qi, Y. X., Yao, Q. P., Chen, X. H., Wang, G. L., Shen, B. R., Han, Y., Gao, L. Z., & Jiang, Z. L. (2015). Neuropeptide Y stimulates proliferation and migration of vascular smooth muscle cells from pregnancy hypertensive rats via Y1 and Y5 receptors. PLoS ONE, 10, e0131124. https://doi.org/10.1371/JOURNAL.PONE.0131124CrossRefPubMedPubMedCentral

94.

Agasse, F., Bernardino, L., Kristiansen, H., Christiansen, S. H., Ferreira, R., Silva, B., Grade, S., Woldbye, D. P., & Malva, J. O. (2008). Neuropeptide Y promotes neurogenesis in murine subventricular zone. Stem cells, 26(6), 1636–45. https://doi.org/10.1634/STEMCELLS.2008-0056CrossRefPubMed

95.

Peng, S., Zhou, Y. L., Song, Z. Y., & Lin, S. (2017). Effects of neuropeptide Y on stem cells and their potential applications in disease therapy. Stem Cells International, 2017(1), 6823917. https://doi.org/10.1155/2017/6823917CrossRefPubMedPubMedCentral

96.

Wu, J., Liu, S., Meng, H., Qu, T., Fu, S., Wang, Z., Yang, J., Jin, D., & Yu, B. (2017). Neuropeptide Y enhances proliferation and prevents apoptosis in rat bone marrow stromal cells in association with activation of the Wnt/β-catenin pathway in vitro. Stem Cell Res, 21, 74–84. https://doi.org/10.1016/J.SCR.2017.04.001CrossRefPubMed

97.

Corvino, V., Marchese, E., Podda, M. V., Lattanzi, W., Giannetti, S., Di Maria, V., Cocco, S., Grassi, C., Michetti, F., & Geloso, M. C. (2014). The neurogenic effects of exogenous neuropeptide Y: Early molecular events and long-lasting effects in the hippocampus of trimethyltin-treated rats. PloS one., 9(2), e88294. https://doi.org/10.1371/JOURNAL.PONE.0088294CrossRefPubMedPubMedCentral

98.

Sigorski, D., Wesołowski, W., Gruszecka, A., Gulczyński, J., Zieliński, P., Misiukiewicz, S., Kitlińska, J., & Iżycka-Świeszewska, E. (2022). Neuropeptide Y and its receptors in prostate cancer: Associations with cancer invasiveness and perineural spread. Journal of Cancer Research and Clinical Oncology, 2022, 1–20. https://doi.org/10.1007/S00432-022-04540-XCrossRef

99.

Galli, S., Naranjo, A., Van Ryn, C., Tilan, J. U., Trinh, E., Yang, C., Tsuei, J., Hong, S. H., Wang, H., Izycka-Swieszewska, E., Lee, Y. C., Rodriguez, O. C., Albanese, C., & Kitlinska, J. (2016). Neuropeptide Y as a biomarker and therapeutic target for neuroblastoma. American Journal of Pathology, 186, 3040–3053. https://doi.org/10.1016/J.AJPATH.2016.07.019CrossRefPubMedPubMedCentral

100.

Tilan, J. U., Krailo, M., Barkauskas, D. A., Galli, S., Mtaweh, H., Long, J., Wang, H., Hawkins, K., Lu, C., Jeha, D., Izycka-Swieszewska, E., Lawlor, E. R., Toretsky, J. A., & Kitlinska, J. B. (2015). Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma–associations with tumor phenotype and survival. Cancer, 121, 697–707. https://doi.org/10.1002/CNCR.29090CrossRefPubMed

101.

Reubi, J. C., Gugger, M., Waser, B., & Schaer, J. C. (2001). Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Research, 61(11), 4636-4641. http://www.ncbi.nlm.nih.gov/pubmed/11389101. Accessed 26 Aug 2018.

102.

Ding, Y., Lee, M., Gao, Y., Bu, P., Coarfa, C., Miles, B., Sreekumar, A., Creighton, C. J., & Ayala, G. (2021). Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance. The Prostate, 81(1), 58–71. https://doi.org/10.1002/pros.24081CrossRefPubMed

103.

Ghersi, G., Chen, W. T., Lee, E. W., & Zukowska, Z. (2001). Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding. Peptides, 22(3), 453-458. http://www.ncbi.nlm.nih.gov/pubmed/11287101. Accessed 22 June 2017.

104.

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70. http://www.ncbi.nlm.nih.gov/pubmed/10647931. Accessed 12 June 2019.

105.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMed

106.

Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12, 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059CrossRefPubMed

107.

Medeiros, P. J., Al-Khazraji, B. K., Novielli, N. M., Postovit, L. M., Chambers, A. F., & Jackson, D. N. (2012). Neuropeptide Y stimulates proliferation and migration in the 4T1 breast cancer cell line. International Journal of Cancer, 131, 276–286. https://doi.org/10.1002/IJC.26350CrossRefPubMed

108.

Lu, C., Everhart, L., Tilan, J., Kuo, L., Sun, C. C. J., Munivenkatappa, R. B., Jönsson-Rylander, A. C., Sun, J., Kuan-Celarier, A., Li, L., Abe, K., Zukowska, Z., Toretsky, J. A., & Kitlinska, J. (2010). Neuropeptide y and its Y2 receptor: Potential targets in neuroblastoma therapy. Oncogene, 29, 5630–5642. https://doi.org/10.1038/ONC.2010.301CrossRefPubMedPubMedCentral

109.

Kitlinska, J., Abe, K., Kuo, L., Pons, J., Yu, M., Li, L., Tilan, J., Everhart, L., Lee, E. W., Zukowska, Z., & Toretsky, J. A. (2005). Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Research, 65, 1719–1728. https://doi.org/10.1158/0008-5472.CAN-04-2192CrossRefPubMed

110.

Vaupel, P., Multhoff, G., Bennet, L., Chan, J., Vaupel, P., Multhoff, G., & Physiol, J. (2021). Revisiting the Warburg effect: Historical dogma versus current understanding. Journal of Physiology, 599, 1745–1757. https://doi.org/10.1113/JP278810CrossRefPubMed

111.

Wang, B., Sheriff, S., Balasubramaniam, A., & Kennedy, M. A. (2015). NMR based metabolomics study of Y2 receptor activation by neuropeptide Y in the SK-N-BE2 human neuroblastoma cell line. Metabolomics, 11, 1243–1252. https://doi.org/10.1007/S11306-015-0782-YCrossRef

112.

Massoner, P., Kugler, K. G., Unterberger, K., Kuner, R., Mueller, L. A. J., Fälth, M., Schäfer, G., Seifarth, C., Ecker, S., Verdorfer, I., Graber, A., Sültmann, H., & Klocker, H. (2013). Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y. PLoS ONE, 8, e55207. https://doi.org/10.1371/journal.pone.0055207CrossRefPubMedPubMedCentral

113.

Papapetrou, E. P. (2016). Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nature Medicine, 22, 1392–1401. https://doi.org/10.1038/NM.4238CrossRefPubMedPubMedCentral

114.

Dietrich, P., Wormser, L., Fritz, V., Seitz, T., de Maria, M., Schambony, A., Kremer, A. E., Günther, C., Itzel, T., Thasler, W. E., Teufel, A., Trebicka, J., Hartmann, A., Neurath, M. F., von Hörsten, S., Bosserhoff, A. K., & Hellerbrand, C. (2020). Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. The Journal of Clinical Investigation, 130, 2509. https://doi.org/10.1172/JCI131919CrossRefPubMedPubMedCentral

115.

Ogasawara, M., Murata, J., Ayukawa, K., & Saiki, I. (1997). Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro. Cancer Letters, 119, 125–130. https://doi.org/10.1016/S0304-3835(97)81762-4CrossRefPubMed

116.

DeMorrow, S., Onori, P., Venter, J., Invernizzi, P., Frampton, G., White, M., Franchitto, A., Kopriva, S., Bernuzzi, F., Francis, H., & Coufal, M. (2011). Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. American Journal of Physiology-Cell Physiology., 300(5), C1078-89. https://doi.org/10.1152/ajpcell.00358.2010CrossRefPubMedPubMedCentral

117.

Medeiros, P. J., Pascetta, S. A., Kirsh, S. M., Al-Khazraji, B. K., & Uniacke, J. (2022). Expression of hypoxia inducible factor–dependent neuropeptide Y receptors Y1 and Y5 sensitizes hypoxic cells to NPY stimulation. Journal of Biological Chemistry, 298(3), 101645. https://doi.org/10.1016/J.JBC.2022.101645CrossRefPubMedPubMedCentral

118.

Pascetta, S. A., Kirsh, S. M., Cameron, M., & Uniacke, J. (2023). Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling. BMC Cancer, 23(1), 494. https://doi.org/10.1186/S12885-023-10993-1CrossRefPubMedPubMedCentral

119.

Zhang, Y., Liu, C. Y., Chen, W. C., Shi, Y. C., Wang, C. M., Lin, S., & He, H. F. (2021). Regulation of neuropeptide Y in body microenvironments and its potential application in therapies: A review. Cell and Bioscience, 11, 1–14. https://doi.org/10.1186/S13578-021-00657-7CrossRef

120.

Zukowska-Grojec, Z., Karwatowska-Prokopczuk, E., Rose, W., Rone, J., Movafagh, S., Ji, H., Yeh, Y., Chen, W. T., Kleinman, H. K., Grouzmann, E., & Grant, D. S. (1998). Neuropeptide Y: A novel angiogenic factor from the sympathetic nerves and endothelium. Circulation Research, 83, 187–195. https://doi.org/10.1161/01.RES.83.2.187CrossRefPubMed

121.

Koulu, M., Movafagh, S., Tuohimaa, J., Jaakkola, U., Kallio, J., Pesonen, U., Geng, Y., Karvonen, M., Vainio-Jylhä, E., Pöllönen, M., & Kaipio-Salmi, K. (2004). Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Annals of medicine., 36(3), 232–40. https://doi.org/10.1080/07853890410031236CrossRefPubMed

122.

Lee, E. W., Grant, D. S., Movafagh, S., & Zukowska, Z. (2003). Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides, 24(1), 99-106. http://www.ncbi.nlm.nih.gov/pubmed/12576090. Accessed 21 June 2017.

123.

Ribatti, D., Marimpietri, D., Pastorino, F., Brignole, C., Nico, B., Vacca, A., & Ponzoni, M. (2004). Angiogenesis in neuroblastoma. Annals of the New York Academy of Sciences, 1028, 133–142. https://doi.org/10.1196/ANNALS.1322.014CrossRefPubMed

124.

Amit, M. (2022). Cancer neuroscience: Evidence for a new hallmark of cancer. Advance. Biology, 6, 2200192. https://doi.org/10.1002/ADBI.202200192CrossRef

125.

Sejda, A., Sigorski, D., Gulczyński, J., Wesołowski, W., Kitlińska, J., & Iżycka-Świeszewska, E. (2020). Complexity of neural component of tumor microenvironment in prostate cancer. Pathobiology, 87, 87–99. https://doi.org/10.1159/000505437CrossRefPubMed

126.

Sigorski, D., Gulczyński, J., Sejda, A., Rogowski, W., & Iżycka-Świeszewska, E. (2021). Investigation of neural microenvironment in prostate cancer in context of neural density, perineural invasion, and neuroendocrine profile of tumors. Frontiers in Oncology, 11, 2602. https://doi.org/10.3389/FONC.2021.710899/BIBTEXCrossRef

127.

Hong, S. H., Tilan, J. U., Galli, S., Izycka-Swieszewska, E., Polk, T., Horton, M., Mahajan, A., Christian, D., Jenkins, S., Acree, R., & Connors, K. (2015). High neuropeptide Y release associates with Ewing sarcoma bone dissemination-In vivo model of site-specific metastases. Oncotarget., 6(9), 7151. https://doi.org/10.18632/ONCOTARGET.3345CrossRefPubMedPubMedCentral

128.

Garner, R., Hong, E., Zhu, S., Adnani, M., Hong, S.-H., Galli, S., & Kitlinska, J. (2018). Abstract 4147: Neuropeptide Y promotes osteolytic activity during bone invasion and metastasis in Ewing sarcoma. Cancer Research, 78, 4147–4147. https://doi.org/10.1158/1538-7445.AM2018-4147CrossRef

129.

Ponzoni, M., Bachetti, T., Corrias, M. V., Brignole, C., Pastorino, F., Calarco, E., Bensa, V., Giusto, E., Ceccherini, I., & Perri, P. (2022). Recent advances in the developmental origin of neuroblastoma: An overview. Journal of Experimental and Clinical Cancer Research, 41, 1–28. https://doi.org/10.1186/S13046-022-02281-W/METRICSCrossRef

130.

He, W. G., Yan, Y., Tang, W., Cai, R., & Ren, G. (2017). Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma. Oncotarget, 8(23), 37730. https://doi.org/10.18632/ONCOTARGET.17146CrossRefPubMedPubMedCentral

131.

Kogner, P., Björk, O., & Theodorsson, E. (1993). Neuropeptide Y in neuroblastoma: Increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Medical and Pediatric Oncology, 21, 317–322. https://doi.org/10.1002/MPO.2950210502CrossRefPubMed

132.

Dötsch, J., Christiansen, H., Hänze, J., Lampert, F., & Rascher, W. (1998). Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Regulatory Peptides, 75–76, 185–190. https://doi.org/10.1016/S0167-0115(98)00067-6CrossRefPubMed

133.

Grünewald, T. G., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018). Ewing sarcoma. Nature reviews Disease primers., 4(1), 5. https://doi.org/10.1038/s41572-018-0003-xCrossRefPubMed

134.

Jagodzińska-Mucha, P., Sobczuk, P., Mikuła, M., Raciborska, A., Dawidowska, A., Kulecka, M., & Ługowska, I. (2021). Mutational landscape of primary and recurrent Ewing sarcoma. Contemporary Oncology/Współczesna Onkologia, 25(4), 241–248. https://doi.org/10.5114/WO.2021.112234CrossRefPubMed

135.

Smith, R., Owen, L. A., Trem, D. J., Wong, J. S., Whangbo, J. S., Golub, T. R., & Lessnick, S. L. (2006). Expression profiling of EWS/FLI identifies NKX2. 2 as a critical target gene in Ewing’s sarcoma. Cancer cell, 9(5), 405–416. https://doi.org/10.1016/J.CCR.2006.04.004CrossRefPubMed

136.

Hancock, J. D., & Lessnick, S. L. (2008). A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle, 7, 250–256. https://doi.org/10.4161/CC.7.2.5229CrossRefPubMed

137.

Kantorovich, V., & Pacak, K. (2010). Pheochromocytoma and paraganglioma. Progress in Brain Research, 182, 343. https://doi.org/10.1016/S0079-6123(10)82015-1CrossRefPubMedPubMedCentral

138.

Rosmaninho-Salgado, J., Alvaro, A. R., Grouzmann, E., Duarte, E. P., & Cavadas, C. (2007). Neuropeptide Y regulates catecholamine release evoked by interleukin-1β in mouse chromaffin cells. Peptides, 28(2), 310–314. https://doi.org/10.1016/J.PEPTIDES.2006.11.015CrossRefPubMed

139.

des Senanayake, P., Denker, J., Bravo, E. L., & Graham, R. M. (1995). Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. The Journal of Clinical Investigation, 96(5), 2503–2509. https://doi.org/10.1172/JCI118310CrossRefPubMed

140.

McCullough, L. A., Egan, T. M., & Westfall, T. C. (1998). Neuropeptide Y inhibition of calcium channels in PC-12 pheochromocytoma cells. American Journal of Physiology-Cell Physiology, 274(5), C1290-C1297. http://www.ncbi.nlm.nih.gov/pubmed/9612216. Accessed 16 Aug 2018.

141.

Eugster, P. J., Maurer, J., Vocat, C., Abid, K., Matter, M., Wuerzner, G., Trepp, R., Fischli, S., Henzen, C., Kolb, W., Bilz, S., Sigrist, S., Beuschlein, F., Nölting, S., Reul, A., Schütze, I., Hubers, S. A., Brown, N. J., & Grouzmann, E. (2022). Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma. Clinica Chimica Acta, 534, 146–155. https://doi.org/10.1016/J.CCA.2022.07.018CrossRef

142.

Takahashi, K., Mouri, T., Itoi, K., Sone, M., Ohneda, M., Murakami, O., Nozuki, M., Tachibana, Y., & Yoshinaga, K. (1987). Increased plasma immunoreactive neuropeptide Y concentrations in phaeochromocytoma and chronic renal failure. Journal of Hypertension, 5, 749–753. https://doi.org/10.1097/00004872-198712000-00020CrossRefPubMed

143.

Helman, L. J., Cohen, P. S., Averbuch, S. D., Cooper, M. J., Keiser, H. R., & Israel, M. A. (1989). Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. Journal of Clinical Oncology, 7, 1720–1725. https://doi.org/10.1200/JCO.1989.7.11.1720CrossRefPubMed

144.

Liu, J., Kahri, A. I., Heikkila, P., & Voutilainen, R. (1999). Regulation of neuropeptide Y mRNA expression in cultured human pheochromocytoma cells. European journal of endocrinology, 141(4), 431-435. http://www.ncbi.nlm.nih.gov/pubmed/10526260. Accessed 21 June 2017.

145.

Amlal, H., Faroqui, S., Balasubramaniam, A., & Sheriff, S. (2006). Estrogen up-regulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line. Cancer Research, 66, 3706–3714. https://doi.org/10.1158/0008-5472.CAN-05-2744CrossRefPubMed

146.

Bhat, R., Thangavel, H., Abdulkareem, N. M., Vasaikar, S., De Angelis, C., Bae, L., Cataldo, M. L., Nanda, S., Fu, X., Zhang, B., & Schiff, R. (2022). NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Scientific Reports., 12(1), 1972. https://doi.org/10.1038/S41598-022-05949-7CrossRefPubMedPubMedCentral

147.

Dawoud, M. M., Abdelaziz, K. K. E., Alhanafy, A. M., Ali, M. S. E. D., & Elkhouly, E. A. B. (2021). Clinical significance of immunohistochemical expression of neuropeptide Y1 receptor in patients with breast cancer in Egypt, Applied Immunohistochemistry and Molecular. Morphology, 29, 277–286. https://doi.org/10.1097/PAI.0000000000000877CrossRef

148.

Medeiros, P. J., & Jackson, D. N. (2013). Neuropeptide Y Y5-receptor activation on breast cancer cells acts as a paracrine system that stimulates VEGF expression and secretion to promote angiogenesis. Peptides, 48, 106–113. https://doi.org/10.1016/J.PEPTIDES.2013.07.029CrossRefPubMed

149.

Liu, J., Wang, X., Sun, J., Chen, Y., Li, J., Huang, J., Du, H., Gan, L., Qiu, Z., Li, H., & Ren, G. (2022). The novel methylation biomarker NPY5R sensitizes breast cancer cells to chemotherapy. Frontiers in Cell and Developmental Biology., 9, 798221. https://doi.org/10.3389/FCELL.2021.798221CrossRefPubMedPubMedCentral

150.

Alshalalfa, M., Nguyen, P. L., Beltran, H., Chen, W. S., Davicioni, E., Zhao, S. G., Rebbeck, T. R., Schaeffer, E. M., Lotan, T. L., Feng, F. Y., & Mahal, B. A. (2019). Transcriptomic and clinical characterization of neuropeptide Y expression in localized and metastatic prostate cancer: Identification of novel prostate cancer subtype with clinical implications. Eur Urol Oncol, 2, 405–412. https://doi.org/10.1016/j.euo.2019.05.001CrossRefPubMedPubMedCentral

151.

Iglesias-Gato, D., Wikström, P., Tyanova, S., Lavallee, C., Thysell, E., Carlsson, J., Hägglöf, C., Cox, J., Andrén, O., Stattin, P., Egevad, L., Widmark, A., Bjartell, A., Collins, C. C., Bergh, A., Geiger, T., Mann, M., & Flores-Morales, A. (2016). The proteome of primary prostate cancer. European Urology, 69, 942–952. https://doi.org/10.1016/j.eururo.2015.10.053CrossRefPubMed

152.

Rasiah, K. K., Kench, J. G., Gardiner-Garden, M., Biankin, A. V., Golovsky, D., Brenner, P. C., Kooner, R., O’Neill, G. F., Turner, J. J., Delprado, W., Lee, C. S., Brown, D. A., Breit, S. N., Grygiel, J. J., Horvath, L. G., Stricker, P. D., Sutherland, R. L., & Henshall, S. M. (2006). Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiology Biomarkers and Prevention, 15, 711–716. https://doi.org/10.1158/1055-9965.EPI-05-0752CrossRef

153.

Kristensen, G., Røder, M. A., Berg, K. D., Elversang, J., Iglesias-Gato, D., Moreira, J., Toft, B. G., & Brasso, K. (2018). Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer. APMIS, 126, 804–813. https://doi.org/10.1111/APM.12886CrossRefPubMed

154.

Ueda, K., Tatsuguchi, A., Saichi, N., Toyama, A., Tamura, K., Furihata, M., Takata, R., Akamatsu, S., Igarashi, M., Nakayama, M., Sato, T.-A., Ogawa, O., Fujioka, T., Shuin, T., Nakamura, Y., & Nakagawa, H. (2013). Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide. Journal of Proteome Research, 12, 4497–4506. https://doi.org/10.1021/pr400547sCrossRefPubMed

155.

Dai, W., Liu, Y., Zhang, Y., Sun, Y., Sun, C., Zhang, Y., & Lv, X. (2019). Expression of neuropeptide Y is increased in an activated human HSC cell line. Scientific Reports, 9(1), 9500. https://doi.org/10.1038/S41598-019-45932-3CrossRefPubMedPubMedCentral

156.

Jeppsson, S., Srinivasan, S., & Chandrasekharan, B. (2017). Neuropeptide Y (NPY) promotes inflammation-induced tumorigenesis by enhancing epithelial cell proliferation. American Journal of Physiology-Gastrointestinal and Liver Physiology, 312(2), G103-G111. https://doi.org/10.1152/ajpgi.00410.2015

157.

Chen, B., Chakrobortty, N., Saha, A. K., & Shang, X. (2023). Identifying colon cancer stage related genes and their cellular pathways. Frontiers in Genetics, 14, 1120185. https://doi.org/10.3389/FGENE.2023.1120185/BIBTEXCrossRefPubMedPubMedCentral

158.

Pérez Tato, B., Juarranz, Á., Nájera, L., Mihm, M. C., Fernández, P., Gilaberte, Y., & González, S. (2017). Neuropeptide Y expression in primary cutaneous melanoma. Journal of the European Academy of Dermatology and Venereology, 31, 443–449. https://doi.org/10.1111/jdv.13836CrossRefPubMed

159.

Gilaberte, Y., Roca, M. J., Garcia-Prats, M. D., Coscojuela, C., Arbues, M. D., & Vera-Alvarez, J. J. (2012). Neuropeptide Y expression in cutaneous melanoma. Journal of the American Academy of Dermatology, 66, e201–e208. https://doi.org/10.1016/j.jaad.2011.02.015CrossRefPubMed

160.

Li, J., Tian, Y., & Wu, A. (2015). Neuropeptide Y receptors: A promising target for cancer imaging and therapy. Regen Biomater, 2, 215. https://doi.org/10.1093/RB/RBV013CrossRefPubMedPubMedCentral

161.

Avvakumova, S., Galbiati, E., Sironi, L., Locarno, S. A., Gambini, L., Macchi, C., Pandolfi, L., Ruscica, M., Magni, P., Collini, M., Colombo, M., Corsi, F., Chirico, G., Romeo, S., & Prosperi, D. (2016). Theranostic nanocages for imaging and photothermal therapy of prostate cancer cells by active targeting of neuropeptide-Y receptor. Bioconjugate Chemistry, 27, 2911–2922. https://doi.org/10.1021/acs.bioconjchem.6b00568CrossRefPubMed

162.

Li, J., Shen, Z., Ma, X., Ren, W., Xiang, L., Gong, A., Xia, T., Guo, J., & Wu, A. (2015). Neuropeptide y Y1 receptors meditate targeted delivery of anticancer drug with encapsulated nanoparticles to breast cancer cells with high selectivity and its potential for breast cancer therapy. ACS Applied Materials and Interfaces, 7, 5574–5582. https://doi.org/10.1021/ACSAMI.5B00270/SUPPL_FILE/AM5B00270_SI_001.PDFCrossRefPubMed

163.

Erondu, N., Gantz, I., Musser, B., Suryawanshi, S., Mallick, M., Addy, C., Cote, J., Bray, G., Fujioka, K., Bays, H., Hollander, P., Sanabria-Bohórquez, S. M., Eng, W. S., Långström, B., Hargreaves, R. J., Burns, H. D., Kanatani, A., Fukami, T., MacNeil, D. J., … Heymsfield, S. B. (2006). Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metabolism, 4, 275–282. https://doi.org/10.1016/J.CMET.2006.08.002CrossRefPubMed

164.

Erondu, N., Wadden, T., Gantz, I., Musser, B., Nguyen, A. M., Bays, H., Bray, G., O’Neil, P. M., Basdevant, A., Kaufman, K. D., Heymsfield, S. B., & Amatruda, J. M. (2007). Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring), 15, 895–905. https://doi.org/10.1038/OBY.2007.620CrossRefPubMed

165.

Sobhani, I., Bergsten, E., Couffin, S., Amiot, A., Nebbad, B., Barau, C., de’Angelis, N., Rabot, S., Canoui-Poitrine, F., Mestivier, D., Pedron, T. (2019). Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures. Proceedings of the National Academy of Sciences, 116(48), 24285-95.https://doi.org/10.1073/PNAS.1912129116/-/DCSUPPLEMENTAL.

166.

Kan, S., Chai, S., Chen, W., & Yu, B. (2019). DNA methylation profiling identifies potentially significant epigenetically-regulated genes in glioblastoma multiforme. Oncology Letters, 18, 1679–1688. https://doi.org/10.3892/OL.2019.10512CrossRefPubMedPubMedCentral

167.

Chatterjee, A., Bararia, A., Ganguly, D., Mondal, P. K., Roy, P., Banerjee, S., Ghosh, S., Gulati, S., Ghatak, S., Chattopadhay, B. K., & Basu, P. (2022). DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort. Cancer Cell International., 22(1), 334. https://doi.org/10.1186/S12935-022-02737-1CrossRefPubMedPubMedCentral

168.

Janssens, K., Vanhoutte, G., Lybaert, W., Demey, W., Decaestecker, J., Hendrickx, K., Kalantari, H. R., Zwaenepoel, K., Pauwels, P., Fransen, E., de Beeck, K. O., Van Camp, G., Rolfo, C., & Peeters, M. (2023). NPY methylated ctDNA is a promising biomarker for treatment response monitoring in metastatic colorectal cancer. Clinical Cancer Research, 29, 1741–1750. https://doi.org/10.1158/1078-0432.CCR-22-1500CrossRefPubMed

169.

Kempf, N., Didier, P., Postupalenko, V., Bucher, B., & Mély, Y. (2015). Internalization mechanism of neuropeptide Y bound to its Y1 receptor investigated by high resolution microscopy. Methods and Applications in Fluorescence, 3(2), 025004. https://doi.org/10.1088/2050-6120/3/2/025004CrossRefPubMed

170.

Kufka, R., Rennert, R., Kaluđerović, G. N., Weber, L., Richter, W., & Wessjohann, L. A. (2019). Synthesis of a tubugi-1-toxin conjugate by a modulizable disulfide linker system with a neuropeptide Y analogue showing selectivity for hY1R-overexpressing tumor cells. Beilstein Journal of Organic Chemistry, 15, 96–105. https://doi.org/10.3762/bjoc.15.11CrossRefPubMedPubMedCentral

171.

Chastel, A., Worm, D. J., Alves, I. D., Vimont, D., Petrel, M., Fernandez, S., Garrigue, P., Fernandez, P., Hindié, E., Beck-Sickinger, A. G., & Morgat, C. (2020). Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides. EJNMMI Research., 10, 1–2. https://doi.org/10.1186/S13550-020-0612-8CrossRef

172.

Schenk, M., Mörl, K., Herzig, S., & Beck-Sickinger, A. G. (2024). Targeted modulation of gene expression through receptor-specific delivery of small interfering RNA peptide conjugates. Journal of Peptide Science. https://doi.org/10.1002/PSC.3611CrossRefPubMed

173.

Loh, K., Herzog, H., & Shi, Y. C. (2015). Regulation of energy homeostasis by the NPY system. Trends in Endocrinology & Metabolism, 26, 125–135. https://doi.org/10.1016/J.TEM.2015.01.003CrossRef

174.

Körner, M., Waser, B., & Reubi, J. C. (2004). High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia. Clinical Cancer Research, 10, 8426–8433. https://doi.org/10.1158/1078-0432.CCR-04-0821CrossRefPubMed

175.

Ruscica, M., Dozio, E., Boghossian, S., Bovo, G., Martos Riaño, V., Motta, M., & Magni, P. (2006). Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology, 147, 1466–1473. https://doi.org/10.1210/en.2005-0925CrossRefPubMed

176.

Lv, X., Zhao, F., Huo, X., Tang, W., Hu, B., Gong, X., Yang, J., Shen, Q., & Qin, W. (2016). Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma. Medical Oncology, 33, 1–13. https://doi.org/10.1007/S12032-016-0785-1/FIGURES/7CrossRef

177.

Goswami, S., Chakroborty, D., Basu, S., Frankel, W., & Sarkar, C. (2020). Abstract 5168: The dual regulatory role of Neuropeptide Y in colon cancer. Cancer Research, 80, 5168–5168. https://doi.org/10.1158/1538-7445.AM2020-5168CrossRef

178.

Chakroborty, D., Goswami, S., Fan, H., Frankel, W. L., Basu, S., & Sarkar, C. (2022). Neuropeptide Y, a paracrine factor secreted by cancer cells, is an independent regulator of angiogenesis in colon cancer. British Journal of Cancer, 127, 1440–1449. https://doi.org/10.1038/S41416-022-01916-1CrossRefPubMedPubMedCentral

179.

Waldmann, J., Fendrich, V., Reichert, M., Hecker, A., Bartsch, D. K., Padberg, W., & Holler, J. P. N. (2018). Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and human samples of pancreatic cancer. Journal of Surgical Research, 223, 230–236. https://doi.org/10.1016/j.jss.2017.11.010CrossRefPubMed

180.

Körner, M., Waser, B., Thalmann, G. N., & Reubii, J. C. (2011). High expression of NPY receptors in the human testis. Molecular and Cellular Endocrinology, 337, 62–70. https://doi.org/10.1016/J.MCE.2011.01.021CrossRefPubMed

181.

Körner, M., Waser, B., & Reubi, J. C. (2004). Neuropeptide Y receptor expression in human primary ovarian neoplasms. Laboratory Investigation, 84, 71–80. https://doi.org/10.1038/LABINVEST.3700009CrossRefPubMed

182.

Jia, R., Li, M., Chang, B., Chen, L., & Ma, J. (2015). Expression of neuropeptide Y and its relationship with molecular and morphological changes in human pituitary adenomas. Cancer Biotherapy and Radiopharmaceuticals, 30, 411–419. https://doi.org/10.1089/cbr.2014.1645CrossRefPubMed

183.

Körner, M., Waser, B., & Reubi, J. C. (2005). Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas. International Journal of Cancer, 115, 734–741. https://doi.org/10.1002/IJC.20948CrossRefPubMed

Title: Neuropeptide Y in cancer—biological functions and potential clinical implications
Authors: Dawid Sigorski
Aleksandra Sejda
Nouran Abualsaud
Ewa Krawczyk
Ewa Izycka-Swieszewska
Joanna Kitlinska
Publication date: 01-03-2025
Publisher: Springer US
Keywords: Metastasis
Neuroblastoma
Neuroblastoma
Sarcoma
Prostate Cancer
Prostate Cancer
Published in: Cancer and Metastasis Reviews / Issue 1/2025
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-024-10237-z

Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer

Review

A possible role of plasmin-dependent activation of TGF-β in cancer-associated thrombosis: Implications for therapy

Open Access
Anticoagulant
Review

Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art

Open Access
Radiotherapy
Review

Mitochondrial alterations and signatures in hepatocellular carcinoma

Open Access
Hepatocellular Carcinoma
Review

The transcription factor FOXQ1 in cancer

Open Access
Metastasis
Review

Vaping and tumor metastasis

Metastasis
Review

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Podcast | Sexual health in older age

Springer Medicine

Neuropeptide Y in cancer—biological functions and potential clinical implications

Abstract

Other articles of this Issue 1/2025

Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer

A possible role of plasmin-dependent activation of TGF-β in cancer-associated thrombosis: Implications for therapy

Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art

Mitochondrial alterations and signatures in hepatocellular carcinoma

The transcription factor FOXQ1 in cancer

Vaping and tumor metastasis

Elevate your expertise in aplastic anemia (Link opens in a new window)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Podcast | Sexual health in older age

Springer Medicine

Abstract

Please log in to get access to this content